Neon Therapeutics   Report issue

For profit Phase 1
Founded: Cambridge MA United States (2015)
Status: Acquired by Biontech (2020)

Organization Overview

First Clinical Trial
2016
NCT02897765
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Neon Therapeutics | Neon Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lung Neoplasms (Phase 1)

Melanoma (Phase 1)

Skin Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 10